Journey Medical (DERM)
(Delayed Data from NSDQ)
$5.05 USD
-0.03 (-0.59%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $5.13 +0.08 (1.58%) 7:58 PM ET
5-Strong Sell of 5 5
D Value D Growth B Momentum D VGM
Brokerage Reports
Journey Medical Corporation [DERM]
Reports for Purchase
Showing records 1 - 20 ( 50 total )
Company: Journey Medical Corporation
Industry: Medical - Drugs
2Q24: Core Business On Track As We Await Nov 4th PDUFA For DFD-29
Provider: Roth Capital Partners, Inc.
Analyst: WHITE J
Company: Journey Medical Corporation
Industry: Medical - Drugs
Company: Journey Medical Corporation
Industry: Medical - Drugs
Company: Journey Medical Corporation
Industry: Medical - Drugs
Company: Journey Medical Corporation
Industry: Medical - Drugs
We are updating our Healthcare coverage to reflect a recent analyst departure and to drop
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Journey Medical Corporation
Industry: Medical - Drugs
Company: Journey Medical Corporation
Industry: Medical - Drugs
3Q23 Recap - Emerging Profitability with Pipeline Catalyst
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Journey Medical Corporation
Industry: Medical - Drugs
Company: Journey Medical Corporation
Industry: Medical - Drugs
Found Money; Qbrexza Deal ($19M) Fortifies Balance Sheet
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Journey Medical Corporation
Industry: Medical - Drugs
Company: Journey Medical Corporation
Industry: Medical - Drugs
2Q23 Recap - Potentially Inflectional Quarter; Raising PT
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Journey Medical Corporation
Industry: Medical - Drugs
Company: Journey Medical Corporation
Industry: Medical - Drugs
1Q23 Recap - Tough Quarter; Eyes on DFD-29 Readout in June
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Journey Medical Corporation
Industry: Medical - Drugs
Company: Journey Medical Corporation
Industry: Medical - Drugs
Company: Journey Medical Corporation
Industry: Medical - Drugs
3Q22 Recap - Challenging Times, but Help on the Way
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Journey Medical Corporation
Industry: Medical - Drugs
Company: Journey Medical Corporation
Industry: Medical - Drugs
Company: Journey Medical Corporation
Industry: Medical - Drugs
Company: Journey Medical Corporation
Industry: Medical - Drugs
2Q22 Recap - Still Optimistic Despite Challenging Quarter
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S